Two members headline latest WHO Prequal announcement

This month, WHO prequalified its first magnesium sulfate product, produced by Inresa Arzneimittel GmbH, a company supported by technical assistance from Concept Foundation. This development marks an important milestone in the field of maternal health as magnesium sulfate is used to treat pre-eclampsia/eclampsia, the second most common cause of maternal deaths worldwide. Read the full announcement here. On the same day, WHO also prequalified the Mifepristone tablet (200mg) produced by Coalition member Beijing Zizhu Pharmaceutical Company, making it the company’s fourth product to be prequalified.

CHAI launches 2016 Family Planning Market Report

More than 77 participants attended a webinar on the recently-launched 2016 CHAI/RHSC Family Planning Market Report. The report – the second in a series - aims to help donors, suppliers, and partners improve their understanding of the current market size and trends for key contraceptive markets. It is a product of the Global Markets Visibility Project, a joint effort between CHAI and the RHSC, which was launched in 2014 under the auspices of the FP2020 MD Working Group. A recording of the webinar can be accessed here.
Julia White joins Secretariat as new Technical Officer

Julia White has joined the Coalition Secretariat as its new Market Development Technical Officer. Julia brings 13+ years’ experience designing, implementing, managing and evaluating international public health projects - especially reproductive health projects. She comes from PSI, where she recently served as Technical Advisor on a women’s health project to increase access to long-term contraception, safe abortion services and post-abortion care in 15 countries. A fluent French speaker, Julia studied at l’Institut d’études politiques de Paris and holds an MHS in International Health from the Johns Hopkins Bloomberg School of Public Health. Julia can be reached at jwhite@rhsupplies.org.

New advocacy papers address market shaping in maternal health

The Coalition, PATH, and R4D have launched a series of advocacy papers detailing how key market challenges are putting women’s lives at risk. The papers, entitled “Stronger markets, increased access to maternal health supplies,” address issues such as the inconsistent availability and poor-quality of oxytocin, misoprostol, and magnesium sulfate. They also propose strategies for solving these issues, thereby preventing the two leading causes of death during pregnancy and childbirth – post-partum hemorrhage and pre-eclampsia/eclampsia. The papers, which recommend actions globally, and in Bangladesh and Nigeria (a paper on Ethiopia is forthcoming) build on a technical analysis commissioned earlier this year by the Coalition. Contact Erin Seaver (eseaver@path.org) for more information on using advocacy for market strengthening to improve maternal health.

Blog: When there’s no Olympic opt-out

Zika has caused more than 1,600 cases of microcephaly and almost 400 stillbirths this year in Brazil alone. And while athletes and fans of this year’s summer Olympics could choose to stay home to avoid contact with the virus, that was not an option for the millions of women and families who live in affected areas, writes the Coalition’s Regional Adviser Milka Dinev, in a Huffington Post blog co-authored with PATH’s Vice-President of Public Health, David Fleming, MD.

Former Coalition Technical Officer to lead SSWG

Ellen Tompsett, the Coalition’s former Technical Officer for Stockouts, was elected this month as Chair of the Systems Strengthening Working Group. Ellen, who is now with the Chemonics Global Health Supply Chain-Procurement and Supply Management project will overlap with current working group leader Leslie Patykewich, who has held the position for more than four years. She will assume her new position as Chair at the Coalition’s General
Membership Meeting in Seattle. The Coalition thanks Leslie for her untiring, inspired, and consistently good-humoured dedication to the Coalition.

**Seattle meeting agenda now online**

More than 360 participants are registered to attend the Coalition’s 17th Membership Meeting in Seattle this October. The meeting will ask Big Questions:

- How far have we come since the 2012 London Family Planning Summit?
- What will contraceptive demand be in 2020?
- How much will we need to spend on contraceptives in 2020, and what funding gap do we face?

An exciting agenda includes the official launch of the Commodity Gap Analysis Report, and the meeting will hear from Microsoft and Starbucks supply chain experts, and from Melinda Gates in a video address. The meeting will also hear about age-specific barriers and strategies to overcome them — from young people themselves. Download the agenda [here](#).

**Coalition membership reaches 390 with 8 new members**

- The [China Family Planning Association (CFPA)](#) is the largest non-governmental network in China active in reproductive health, family planning and HIV/AIDS prevention and care.
- US-based [Population Connection](#), the country’s largest grassroots population organization with over 40,000 members, works to ensure that every woman has access to the contraceptive products and services she needs.
- The [Medical Export Group](#) in the Netherlands is an international wholesaler that supplies pharmaceuticals and other medical products for global healthcare development.
- [TESS Development Advisors](#) is a technical support agency in Switzerland focusing on pharmaceutical markets in low-income countries and supporting access to essential medicines and basic healthcare services.
- In Colombia, [Fundación Educación para la Salud reproductiva - ESAR](#) is a non-profit working to make clinical services for the comprehensive management of unwanted pregnancy available to the largest number of women in Latin America.
- The [China Wood (Group) Co., Ltd.](#) is one of the largest wood traders in China and its medical programs cover medical services, pharmaceutical distribution and production with a special focus on reproductive health.
- **Evofem Biosciences** is a US-based biotechnology company that develops and commercializes innovative products such as Amphora®, a vaginal contraceptive gel, and the Nestorone® Ring, a one-year contraceptive vaginal ring, both of which have completed Phase III clinical studies.
- **Mylan Laboratories Ltd.** in India is a wholly-owned subsidiary of Mylan Inc., the world's third largest generic pharmaceutical company.

**In the calendar**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>4-5 Oct</td>
<td>The 2016 EuroNGOs Conference</td>
<td>Paris, France</td>
</tr>
<tr>
<td>10-14 Oct</td>
<td>17th General Membership Meeting of the Reproductive Health Supplies Coalition</td>
<td>Seattle, USA</td>
</tr>
<tr>
<td>10-12 Nov</td>
<td>Sexual and Reproductive Health and Rights Conference</td>
<td>Wellington, NZ</td>
</tr>
<tr>
<td>16-18 Nov</td>
<td>9th Global Health Supply Chain Summit</td>
<td>Dar es Salaam, TZ</td>
</tr>
<tr>
<td>27-30 Nov</td>
<td>9th Asia Pacific Conference on Reproductive and Sexual Health and Rights</td>
<td>Da Nang, Vietnam</td>
</tr>
<tr>
<td>28-29 Nov</td>
<td>13th International Inter-Ministerial Conference on Population and Development</td>
<td>Dakar, Senegal</td>
</tr>
</tbody>
</table>